|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.70 USD | +1.25% |
|
+2.48% | +29.36% |
| 04:31am | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 06/08 | (EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | +1.25% | +2.48% | +29.36% | +51.36% | +233.53% | 1.41TCr |  |  | |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
